180 related articles for article (PubMed ID: 34036745)
1. Weight changes after antiretroviral therapy initiation in CoRIS (Spain): a prospective multicentre cohort study.
Martínez-Sanz J; Blanco JR; Muriel A; Pérez-Elías MJ; Rubio-Martín R; Berenguer J; Peraire J; Bernal E; Martínez OJ; Serrano-Villar S; Moreno S;
J Int AIDS Soc; 2021 May; 24(5):e25732. PubMed ID: 34036745
[TBL] [Abstract][Full Text] [Related]
2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
3. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
5. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
6. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
7. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
Jarrin I; Suarez-Garcia I; Moreno C; Tasias M; Del Romero J; Palacios R; Peraire J; Gorgolas M; Moreno S;
Antivir Ther; 2019; 24(3):167-175. PubMed ID: 30747107
[TBL] [Abstract][Full Text] [Related]
8. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
10. Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study.
Hirigo AT; Yilma D; Astatkie A; Debebe Z
Ann Med; 2023; 55(2):2242250. PubMed ID: 37531412
[TBL] [Abstract][Full Text] [Related]
11. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
12. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
Capeau J; Lagathu C; Béréziat V
Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
[TBL] [Abstract][Full Text] [Related]
13. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
14. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
15. Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study).
Gómez-Ayerbe C; Palacios R; Mayorga M; Navarrete MN; Ferra S; Ruiz I; Garcia C; Castaño M; Merino D; Collado A; Hidalgo-Tenorio C; Delgado M; Rivero A; Santos J
Int J STD AIDS; 2022 Nov; 33(13):1119-1123. PubMed ID: 36071543
[TBL] [Abstract][Full Text] [Related]
16. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
17. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
[TBL] [Abstract][Full Text] [Related]
18. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
20. Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug.
Pantazis N; Papastamopoulos V; Antoniadou A; Adamis G; Paparizos V; Metallidis S; Sambatakou H; Psichogiou M; Chini M; Chrysos G; Panagopoulos P; Sipsas NV; Barbunakis E; Gogos C; Touloumi G;
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
